share_log

BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 19.9%

Financial News Live ·  Jan 7, 2023 09:32

Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) traded down 19.9% during mid-day trading on Thursday . The company traded as low as $0.03 and last traded at $0.26. 812 shares changed hands during trading, a decline of 63% from the average session volume of 2,171 shares. The stock had previously closed at $0.33.

bioAffinity Technologies Stock Performance

The firm's 50-day moving average is $0.44.

Get bioAffinity Technologies alerts:

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Armistice Capital LLC purchased a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) in the third quarter, according to its most recent filing with the SEC. The firm purchased 204,082 shares of the company's stock, valued at approximately $72,000.

bioAffinity Technologies Company Profile

(Get Rating)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.

See Also

  • Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
  • MarketBeat: Week in Review 01/02-01/06
  • Why is the CrowdStrike Stock Price Struggling?
  • Four Undervalued Healthcare Stocks for 2023
  • WWE Stock: Vince McMahon Wants Back In The Show
  • NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment